Leading biotechnology company Genentech recently announced that it is doubling its investment in a new Holly Springs manufacturing facility—bringing its investment to approximately $2 billion.
The investment is to create a state-of-the-art manufacturing facility, set to be operational by 2029, that will create treatments for metabolic conditions like obesity. The facility, which broke ground in August 2025, is expected to support more than 2,000 jobs, including more than 500 high-wage manufacturing and more than 1,500 construction jobs.
“Genentech’s increased investment in Holly Springs creates durable jobs and strengthens our life sciences sector,” said Governor Josh Stein. “This expansion reinforces North Carolina’s role in supporting innovation, workforce development, and long-term economic opportunity.”
Genentech decided to increase its investment in Holly Springs, a growing hub for biopharmaceutical innovation, because of its highly skilled local workforce, strong academic institutions, and proximity to other leading life science companies in the Raleigh-Durham area.
“We are especially grateful for the partnership and support of North Carolina Governor Josh Stein and Holly Springs Mayor Mike Kondratick, alongside the Holly Springs Town Council, whose collaboration has been essential to advancing this project,” said Genentech CEO Ashley Magargee.
